Is TLIS a buy or a sell?
The Discounted Cash Flow (DCF) valuation of Talis Biomedical Corp (TLIS) is (1.61) USD. With the latest stock price at 4.38 USD, the upside of Talis Biomedical Corp based on DCF is -136.8%. This means that TLIS is a sell according to the DCF valuation model.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 6.5% | 5.8% |
| Long-term Growth Rate | 3.0% - 4.7% | 3.9% |
| Fair Price | (45.28) - 1.48 | (1.61) |
| Upside | -1133.7% - -66.3% | -136.8% |